Business
Ten further MAAs submitted in
Ten further MAAs submitted in.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n RNS Number : 1091X Allergy Therapeutics PLC 01 December 2010 \n \n\nWednesday 1 December 2010\n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or \"the Company\")\n \nTen further Marketing Authorisation Applicationssubmitted in Germany \n \nAllergy Therapeutics, the specialist pharmaceutical company focused on allergy vaccination, announces that, in line with its stated plan, it has submitted 10 Marketing Authorisation Applications ('MAAs') to the Paul Ehrlich Institute, the Regulatory Authority for biological products in Germany. This achievement has been in response to the introduction of the Therapeutic Allergen Regulation ('TAV') which has changed the regulatory landscape in Germany. To date many products have been available in Germany on a 'named patient' basis, however, as a result of the TAV all immunotherapy products containing common allergens (grass, trees, house dust mites and insect venoms) will need Marketing Authorisations by 2017.\n \nSince 2008, Allergy Therapeutics has reviewed its product portfolio and has been preparing MAAs for its top 10 products in the Pollinex Quattro, Tyrosin TU t.o.p. and Oralvac Compact ranges. This has been a major project that has required significant investment over the past two years and will result in the Company continuing to offer an attractive portfolio of products. \n \nManuel Llobet, Chief Executive of Allergy Therapeutics, said: \n \n\"The regulatory landscape in Germany, the largest immunotherapy market in Europe, has been undergoing a significant period of change. Our response has been a crucial project for Allergy Therapeutics and its completion is a major achievement. The regulatory changes should favour the Company as the market will become focused on evidence-based, approved, value-added immunotherapy products and Allergy Therapeutics is well-placed to deliver a range of such products.\"\n \n \nFor further information\n \n\n\n\n\nAllergy Therapeutics\nManuel Llobet, Chief Executive\nTom Holdich, R&D Director\n\n\n+44 (0) 1903 845 820\n\n\n\n\n\n\n\n\n\n\n\n\nNomura Code Securities\nJuliet Thompson/ Clare Terlouw \n\n\n+44 (0) 207 776 1200\n\n\n\n\n\n\n\n\n\n\n\n\nFinancial Dynamics\nBen Brewerton / Susan Quigley\n\n\n+44 (0) 207 831 3113\n\n\n\n\n \n \nAbout Pollinex® Quattro\n \nPollin...